These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 11567200

  • 21. Timeliness of MMR vaccination and barriers to vaccination in preschool children.
    Jeong YW, Park BH, Kim KH, Han YR, Go UY, Choi WS, Kong KA, Park H.
    Epidemiol Infect; 2011 Feb; 139(2):247-56. PubMed ID: 20412613
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
    Redd SC, King GE, Heath JL, Forghani B, Bellini WJ, Markowitz LE.
    J Infect Dis; 2004 May 01; 189 Suppl 1():S116-22. PubMed ID: 15106100
    [Abstract] [Full Text] [Related]

  • 27. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P, Lim FS, Han HH, Willems P.
    Infection; 2007 Oct 01; 35(5):326-33. PubMed ID: 17710370
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Evaluation of vaccine coverage in children from 2 to 4 years old in South-Eastern France].
    Guagliardo V, Bouhnik AD, Verger P.
    Arch Pediatr; 2007 Apr 01; 14(4):338-44. PubMed ID: 17229558
    [Abstract] [Full Text] [Related]

  • 32. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.
    LeBaron CW, Bi D, Sullivan BJ, Beck C, Gargiullo P.
    Pediatrics; 2006 Oct 01; 118(4):1422-30. PubMed ID: 17015532
    [Abstract] [Full Text] [Related]

  • 33. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.
    France EK, Glanz J, Xu S, Hambidge S, Yamasaki K, Black SB, Marcy M, Mullooly JP, Jackson LA, Nordin J, Belongia EA, Hohman K, Chen RT, Davis R, Vaccine Safety Datalink Team.
    Pediatrics; 2008 Mar 01; 121(3):e687-92. PubMed ID: 18310189
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Parental vaccine safety concerns: results from the National Immunization Survey, 2001-2002.
    Allred NJ, Shaw KM, Santibanez TA, Rickert DL, Santoli JM.
    Am J Prev Med; 2005 Feb 01; 28(2):221-4. PubMed ID: 15710279
    [Abstract] [Full Text] [Related]

  • 37. Evaluation of immunity against rubella in Iranian after mass campaign for measles-rubella vaccination on December 2003.
    Hamkar R, Jalilvand S, Mokhtari-Azad T, Jelyani KN, Nategh R.
    Am J Infect Control; 2006 Nov 01; 34(9):588-92. PubMed ID: 17097454
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Measles, mumps, and rubella vaccine coverage in 2 year old children in East Lancashire--better than it looks.
    Clark A, Marshall R.
    Commun Dis Public Health; 1999 Jan 01; 2(1):50-3. PubMed ID: 10462897
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.